行情

AYTU

AYTU

Aytu BioScience
NASDAQ

实时行情|Nasdaq Last Sale

8.30
+0.64
+8.36%
盘后: 8.23 -0.07 -0.84% 19:50 01/20 EST
开盘
7.70
昨收
7.66
最高
8.37
最低
7.55
成交量
90.49万
成交额
--
52周最高
29.90
52周最低
3.350
市值
1.43亿
市盈率(TTM)
-3.6620
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
专业整合商:Biopharma Aytu希望通过收购和许可来推动到2021年的增长
The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational p...
Benzinga · 01/06 12:58
Aytu BioSicence报告COVID-19患者的Helight安全性研究完成
Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs announced the completion of the safety
Benzinga · 2020/12/28 13:06
每日生物技术动向:辉瑞-生物技术公司获得FDA小组的支持,赛诺菲-GSK披露了疫苗计划的延迟,华尔街有4家生物技术公司首次亮相
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 10)
Benzinga · 2020/12/11 13:11
上午市场更新:市场涨跌互现; Adobe收益顶视图
Following the market opening Thursday, the Dow traded down 0.12% to 30,033.62 while the NASDAQ rose 0.32% to 12,378.96. The S&P also rose, gaining 0.02% to 3,673.72.
Benzinga · 2020/12/10 15:12
研究Aytu BioScience的已用资本回报率
During Q1, Aytu BioScience (NASDAQ: AYTU) brought in sales totaling $13.52 million. However, earnings decreased 46.39%, resulting in a loss of $3.56 million. Aytu BioScience collected $14.86 million in revenue during Q4, but reported earnings showed a $6.63 million loss.What Is Return On Capital Employed? Changes in earnings and sales indicate shifts in Aytu BioScience's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Aytu BioScience posted an ROCE of -0.04%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.View more earnings on AYTUROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Aytu BioScience is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.For Aytu BioScience, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.Q1 Earnings Insight Aytu BioScience reported Q1 earnings per share at $-0.04/share, which beat analyst predictions of $-0.05/share.See more from Benzinga * Click here for options trades from Benzinga * Stocks That Hit 52-Week Highs On Wednesday * 12 Healthcare Stocks Moving In Wednesday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 2020/12/09 15:30
Aytu Bioscience 8-K Shows Co. Established Purchasing Relationship With US Supplier Of Emergency Use Authorization Authorized Antigen Tests
The Company recently established a purchasing relationship with a U.S. supplier of Emergency Use Authorization (EUA) authorized antigen tests. Antigen tests rapidly detect the presence of the SARS-CoV-2 virus antigen via
Benzinga · 2020/12/02 15:34
Aytu BioScience Q1 EPS $(0.04) Beats $(0.05) Estimate, Sales $13.50M Beat $13.33M Estimate
Aytu BioScience (NASDAQ:AYTU) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 87.5 percent increase over losses of $(0.32) per share from the
Benzinga · 2020/11/12 21:03
The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 11)
Benzinga · 2020/11/12 12:44
更多
财务预测
每股收益每股净资产每股现金流
实际值(美元)
预测值(美元)
利润表更多
净利润营业总收入营业利润
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流(美元)
同比(%)
了解AYTU最新的财务预测,通过AYTU每股收益,每股净资产,每股现金流等数据分析Aytu BioScience近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测AYTU价格均价为23.60,最高价位30.00,最低价为17.20。
EPS
机构持股
总机构数: 95
机构持股: 389.41万
持股比例: 22.58%
总股本: 1,724.63万
类型机构数股数
增持
20
42.13万
建仓
31
-3.78万
减持
18
7.84万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.31%
制药与医学研究
-0.03%
高管信息
Chairman/Chief Executive Officer/Director
Joshua Disbrow
Chief Financial Officer/Treasurer/Secretary
David Green
Chief Operating Officer
Jarrett Disbrow
Executive Vice President
Matthew Phillips
Director
Steven Boyd
Director
Ketan Mehta
Independent Director
Gary Cantrell
Independent Director
Carl Dockery
Independent Director
John Donofrio
Independent Director
Michael Macaluso
  • 分红
  • 拆股
  • 内部人交易
暂无数据
注册即可获得3个月
免费美股Level2深度行情
(Nasdaq Totalview)
立即领取
AYTU 简况
Aytu BioScience Inc是一家专业制药公司。该公司向初级医疗和儿科市场推广一系列的处方药物。其初级医疗产品组合包括Natesto,一种针对性腺机能减退男性的睾丸素鼻用制剂;ZolpiMist,一种口服喷剂处方安眠药;以及Tuzistra XR,一种12小时含可待因止咳糖浆。该公司的儿科产品组合包括AcipHex Sprinkle,一种雷贝拉唑钠颗粒剂和常用质子泵抑制剂;头孢克洛,一种二代头孢菌素抗生素;Karbinal ER,一种可释放的羧甲基胺,可以治疗多种过敏性疾病,以及Poly-Vi-Flor和Tri-Vi-Flor,是两种氟补充处方药,其中包含多种氟和维生素,适用于患有氟缺乏的婴幼儿。
展开

微牛提供Aytu Bioscience Inc(NASDAQ-AYTU)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的AYTU股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易AYTU股票基本功能。